ArticleAmerican journal of translational research2024
Clinical value of CD3
Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to investigate the the content of CD3
methodsThis retrospective study included patients from the Affiliated Jiangning Hospital of Nanjing Medical University between December 2021 and December 2023. A total of 65 AECOPD patients with RF were selected as the RF group, 64 AECOPD patients without RF as the AE group, and 60 patients with stable COPD as the COPD group. Data on gender, age, course of disease, smoking, alcohol consumption, history of hypertension and diabetes were collected. Serum levels of IL-2 and IL-8 were detected by enzyme-linked immunosorbent assay (ELISA). Arterial oxygen partial pressure (PaO
resultsExpression levels of IL-2 in the COPD group, AE group, and RF group were 2.91±0.55, 2.21±0.48 and 1.39±0.43, respectively, while the expression levels of IL-8 were 31.01±4.86, 38.02±5.16 and 44.43±6.54, respectively. The percentages of CD3
conclusionsThe combined assessment of serum IL-2, and IL-8 levels and positive CD3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.